SyntekaBio Inc (226330) — Cash Flow-to-Debt Ratio
SyntekaBio Inc (226330) has a Cash Flow-to-Debt Ratio of -0.09x as of September 2025, meaning its operating cash flow of ₩-2.01 Billion could theoretically repay 0% of its total liabilities (₩21.59 Billion) in one year. See how much free cash does SyntekaBio Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SyntekaBio Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for SyntekaBio Inc across 8 annual periods. Also explore SyntekaBio Inc (226330) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for SyntekaBio Inc (2017–2024)
Year-by-year debt coverage analysis for SyntekaBio Inc. For market capitalisation and broader financial context, see SyntekaBio Inc (226330) total market value.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.56x | ₩-10.51 Billion | ₩18.77 Billion | ▼ -50.3% |
| 2023 | -0.37x | ₩-8.08 Billion | ₩21.69 Billion | ▼ -6.0% |
| 2022 | -0.35x | ₩-8.51 Billion | ₩24.23 Billion | ▼ -134.1% |
| 2021 | -0.15x | ₩-6.04 Billion | ₩40.25 Billion | ▲ +89.6% |
| 2020 | -1.44x | ₩-4.67 Billion | ₩3.24 Billion | ▲ +19.3% |
| 2019 | -1.79x | ₩-3.28 Billion | ₩1.84 Billion | ▼ -690.6% |
| 2018 | -0.23x | ₩-2.37 Billion | ₩10.47 Billion | ▲ +51.9% |
| 2017 | -0.47x | ₩-2.49 Billion | ₩5.29 Billion | — |